{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:39:46Z","timestamp":1787315986650,"version":"build-2736575974"},"reference-count":40,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,4,15]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To comparatively investigate the differential effect of second-line tumour necrosis factor inhibitors (TNFis) versus other biological agents on cardiovascular disease (CVD) risk-associated biomarkers in patients with rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the serum levels of lipoprotein-associated apoproteins ApoA1 and ApoB100 and lipoprotein(a) (Lp(a)) and the leptin\/adiponectin ratio (LAR) as an insulin resistance proxy in patients with RA from the Rotation Or Change (ROC) trial treated with either a second-line TNFi or another biologic (tocilizumab (TCZ), rituximab or abatacept) at baseline and week 24. We compared the changes in biomarker levels in each group and according to the EULAR response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 300 patients enrolled in the ROC trial, 203 were included in the study, including 96 in the second-line TNFi group and 107 in the other biological group. The measured biomarkers did not deteriorate between baseline and week 24 regardless of the group. A greater improvement in the LAR was noted in the other biological group (median (IQR) \u22120.12\u2009ng\/\u00b5g (\u22120.58 to 0.31) vs 0.04 (\u22120.19 to 0.43), p=0.033), and a greater improvement in the Lp(a) level was observed following treatment with TCZ than with a TNFi (\u22120.05\u2009g\/L (\u22120.11 to \u22120.01) vs \u22120.01\u2009g\/L (\u22120.02 to 0.01), p&lt;0.001). When considering the patients\u2019 responses to treatment, improved biomarkers were mainly observed in the EULAR responders in each treatment group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TNFis and non-TNFis were neutral on improved CVD risk-associated biomarkers in patients with RA insufficiently controlled by TNFis. TCZ could be associated with a better improvement concerning Lp(a) and LAR than TNFis. This improvement could be related to a good therapeutic response, thereby supporting the need of good control of RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01000441\">NCT01000441<\/jats:ext-link>\n                      , registered on 22 October 2009.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-000897","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T05:29:00Z","timestamp":1563773340000},"page":"e000897","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct01000441","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01000441","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01331837","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-8449","authenticated-orcid":false,"given":"Alexandre","family":"Virone","sequence":"first","affiliation":[{"name":"Rheumatology Department, H\u00f4pital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Bastard","sequence":"additional","affiliation":[{"name":"Biochemistry Department, H\u00f4pital Tenon, AP-HP, Paris, France"},{"name":"Faculty of Medicine Sorbonne Universit\u00e9, CRSA INSERM UMRS_938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Fellahi","sequence":"additional","affiliation":[{"name":"Biochemistry Department, H\u00f4pital Tenon, AP-HP, Paris, France"},{"name":"Faculty of Medicine Sorbonne Universit\u00e9, CRSA INSERM UMRS_938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Capeau","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Sorbonne Universit\u00e9, CRSA INSERM UMRS_938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Rouanet","sequence":"additional","affiliation":[{"name":"StatEthic, Levallois-Perret, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[{"name":"Rheumatology Department, H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[{"name":"Epidemiology and Statistics Research Centre, Inserm UMR 1153, Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Berenbaum","sequence":"additional","affiliation":[{"name":"Rheumatology Department, H\u00f4pital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France"},{"name":"Faculty of Medicine Sorbonne Universit\u00e9, CRSA INSERM UMRS_938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[{"name":"Rheumatology Department, H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Sellam","sequence":"additional","affiliation":[{"name":"Rheumatology Department, H\u00f4pital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France"},{"name":"Faculty of Medicine Sorbonne Universit\u00e9, CRSA INSERM UMRS_938, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,21]]},"reference":[{"key":"2025090313342083000_5.2.e000897.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200726"},{"key":"2025090313342083000_5.2.e000897.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"2025090313342083000_5.2.e000897.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.10089"},{"key":"2025090313342083000_5.2.e000897.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000099844.31524.05"},{"key":"2025090313342083000_5.2.e000897.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00114-3"},{"key":"2025090313342083000_5.2.e000897.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135871"},{"key":"2025090313342083000_5.2.e000897.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.804146"},{"key":"2025090313342083000_5.2.e000897.8","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"The Lancet"},{"key":"2025090313342083000_5.2.e000897.9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01276.x"},{"key":"2025090313342083000_5.2.e000897.10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/03009742.2013.877158","article-title":"The apoB\/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis","volume":"43","author":"\u00d6hman","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2025090313342083000_5.2.e000897.11","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.6.598"},{"key":"2025090313342083000_5.2.e000897.12","doi-asserted-by":"crossref","unstructured":"Kang Y , Park H-J , Kang M-I , et al . Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2013;15.doi:10.1186\/ar4384","DOI":"10.1186\/ar4384"},{"key":"2025090313342083000_5.2.e000897.13","first-page":"596","article-title":"High-Grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis","volume":"26","author":"Gonzalez-Gay","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313342083000_5.2.e000897.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1508-3"},{"key":"2025090313342083000_5.2.e000897.15","unstructured":"ASL L , Symmons DPM , Lunt M , et al . Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2017."},{"key":"2025090313342083000_5.2.e000897.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.127597"},{"key":"2025090313342083000_5.2.e000897.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201148"},{"key":"2025090313342083000_5.2.e000897.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1303-y"},{"key":"2025090313342083000_5.2.e000897.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.04.031"},{"key":"2025090313342083000_5.2.e000897.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204345"},{"key":"2025090313342083000_5.2.e000897.21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"2025090313342083000_5.2.e000897.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207870"},{"key":"2025090313342083000_5.2.e000897.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130709","article-title":"The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and Tociliziumab","volume":"10","author":"Provan","year":"2015","journal-title":"PLoS One"},{"key":"2025090313342083000_5.2.e000897.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1095-1"},{"key":"2025090313342083000_5.2.e000897.25","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.2.202"},{"key":"2025090313342083000_5.2.e000897.26","doi-asserted-by":"crossref","unstructured":"Mathieu S , Couderc M , Pereira B , et al . Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. BTT 2013.doi:10.2147\/BTT.S52003","DOI":"10.2147\/BTT.S52003"},{"key":"2025090313342083000_5.2.e000897.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207872"},{"key":"2025090313342083000_5.2.e000897.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13512"},{"key":"2025090313342083000_5.2.e000897.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"2025090313342083000_5.2.e000897.30","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a Multi\u2010Database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"2025090313342083000_5.2.e000897.31","first-page":"310","article-title":"Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept","volume":"36","author":"Generali","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313342083000_5.2.e000897.32","unstructured":"Giles J , Sattar N , Gabriel S , et al . Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, Noninferiority, phase 4 clinical trial. ACR Meet. Abstr 2016."},{"key":"2025090313342083000_5.2.e000897.33","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jacl.2017.02.018","article-title":"Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project","volume":"11","author":"Garc\u00eda-G\u00f3mez","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2025090313342083000_5.2.e000897.34","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R300019-JLR200"},{"key":"2025090313342083000_5.2.e000897.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206411"},{"key":"2025090313342083000_5.2.e000897.36","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"The Lancet"},{"key":"2025090313342083000_5.2.e000897.37","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.745013"},{"key":"2025090313342083000_5.2.e000897.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.37916"},{"key":"2025090313342083000_5.2.e000897.39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.2016.11409","article-title":"Pragmatic Trials: Practical Answers to \"Real World\" Questions","volume":"316","author":"Sox","year":"2016","journal-title":"JAMA"},{"key":"2025090313342083000_5.2.e000897.40","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"The Lancet"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-000897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:34:28Z","timestamp":1756931668000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-000897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,7,21]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/rmdopen-2019-000897"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-000897","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}